Brain targeting efficiency of antimigrain drug loaded mucoadhesive intranasal nanoemulsion

Abdou, Ebtsam M; Kandil, Soha M; Miniawy, Hala M.F. El

doi:10.1016/j.ijpharm.2017.07.030

Cited by 98 publications

(40 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chitosan-based emulsions have been shown to improve drug deposition in the brain following intranasal delivery. For instance, 0.3% (w/v) chitosan significantly increased the brain deposition of zolmitriptan when administered in an oil-in-water emulsion [201]. It has been reported that when resveratrol lipid microparticles were coated with chitosan and administered intranasally as lipid particles at the dose of 60 µm to a rat model, a dramatic and specific 6-fold increase, without any detectable systemic exposure, was observed in its distribution to the cerebrospinal fluid [202].…”

Section: Nanoparticles Composed Of Chitosan and Chitosan Derivativesmentioning

confidence: 99%

Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders

et al. 2020

View full text Add to dashboard Cite

Although the global prevalence of neurological disorders such as Parkinson's disease, Alzheimer's disease, glioblastoma, epilepsy, and multiple sclerosis is steadily increasing, effective delivery of drug molecules in therapeutic quantities to the central nervous system (CNS) is still lacking. The blood brain barrier (BBB) is the major obstacle for the entry of drugs into the brain, as it comprises a tight layer of endothelial cells surrounded by astrocyte foot processes that limit drugs' entry. In recent times, intranasal drug delivery has emerged as a reliable method to bypass the BBB and treat neurological diseases. The intranasal route for drug delivery to the brain with both solution and particulate formulations has been demonstrated repeatedly in preclinical models, including in human trials. The key features determining the efficacy of drug delivery via the intranasal route include delivery to the olfactory area of the nares, a longer retention time at the nasal mucosal surface, enhanced penetration of the drugs through the nasal epithelia, and reduced drug metabolism in the nasal cavity. This review describes important neurological disorders, challenges in drug delivery to the disordered CNS, and new nasal delivery techniques designed to overcome these challenges and facilitate more efficient and targeted drug delivery. The potential for treatment possibilities with intranasal transfer of drugs will increase with the development of more effective formulations and delivery devices. Figure 1. Schematic demonstrating various transport systems that shuttle molecules across the BBB. Very small amount of water-soluble compounds cross through the tight junctions (paracellular), whereas lipid-soluble agents traverse via the transcellular lipophilic pathway. Selective transport systems exist for glucose, amino acids, nucleosides, and other substances, in addition to specific receptor-mediated endocytosis for certain proteins such as insulin and transferrin. (AZT = azathioprine). List of CNS Diseases Parkinson's Disease (PD)PD, occurring primarily in the substantia nigra, is the second-most common neurodegenerative disease, leading to the development of bradykinesia and tremors of cardinal motor functions ( Figure 2) [3]. PD models specifically show a decrease in dopamine transporters, which are responsible for dopamine uptake by dopaminergic neurons and progression of neuronal communications. Reduced Figure 1. Schematic demonstrating various transport systems that shuttle molecules across the BBB. Very small amount of water-soluble compounds cross through the tight junctions (paracellular), whereas lipid-soluble agents traverse via the transcellular lipophilic pathway. Selective transport systems exist for glucose, amino acids, nucleosides, and other substances, in addition to specific receptor-mediated endocytosis for certain proteins such as insulin and transferrin. (AZT = azathioprine). List of CNS Diseases Parkinson's Disease (PD)PD, occurring primarily in the substantia nigra, is the second-most common neuro...

show abstract

Section: Nanoparticles Composed Of Chitosan and Chitosan Derivativesmentioning

confidence: 99%

Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A mucoadhesive NE of zolmitriptan is another example that showed the enhanced brain permeation of zolmitriptan from a chitosan-based mucoadhesive NE. A 2.8-fold higher brain AUC (0-8) compared to the IV and brain targeting parameters of 164.77 and 9.61 for DTE% and DTP%, respectively, were attained [168]. Other studies investigated hyaluronic acid for the development of mucoadhesive nasal NEs for brain delivery.…”

Section: Nanocapsules (Ncs)mentioning

confidence: 99%

Intranasal Nanoparticulate Systems as Alternative Route of Drug Delivery

Alshweiat

Ambrus

Csóka

2019

CMC

View full text Add to dashboard Cite

There is always a need for alternative and efficient methods of drug delivery. The nasal cavity can be considered as a non-invasive and efficient route of administration. It has been used for local, systemic, brain targeting, and vaccination delivery. Although many intranasal products are currently available on the market, the majority is used for local delivery with fewer products available for the other targets. As nanotechnology utilization in drug delivery has rapidly spread out, the nasal delivery has become attractive as a promising approach. Nanoparticulate systems facilitate drug transportation across the mucosal barrier, protect the drug from nasal enzyme degradation, enhance the delivery of vaccines to the lymphoid tissue of the nasal cavity with an adjuvant activity, and offer a way for peptide delivery into the brain and the systemic circulation, in addition to their potential for brain tumor treatment. This review article aims at discussing the potential benefit of the intranasal nanoparticulate systems, including nanosuspensions, lipid and surfactant, and polymer-based nanoparticles as regards productive intranasal delivery. The aim of this review is to focus on the topicalities of nanotechnology applications for intranasal delivery of local, systemic, brain, and vaccination purposes during the last decade, referring to the factors affecting delivery, regulatory aspects, and patient expectations. This review further identifies the benefits of applying the Quality by Design approaches (QbD) in product development. According to the reported studies on nanotechnology-based intranasal delivery, potential attention has been focused on brain targeting and vaccine delivery with promising outcomes. Despite the significant research effort in this field, nanoparticle-based products for intranasal delivery are not available. Thus, further efforts are required to promote the introduction of intranasal nanoparticulate products that can meet the requirements of regulatory affairs with high patient acceptance.

show abstract

“…Zolmitriptan is used to treat migraine but it suffers from low bioavailability after administration either by oral or nasal route. In order to enhance its bioavailability, it was incorporated into nanoemulsion formulation for targeted delivery from the nose to the brain [110]. The formulation exhibited a high permeation coefficient on the nasal mucosa than the drug solution.…”

Section: Emulsionsmentioning

confidence: 99%

Chitosan-Based Nanocarriers for Nose to Brain Delivery

Aderibigbe

Naki

2019

Applied Sciences

View full text Add to dashboard Cite

In the treatment of brain diseases, most potent drugs that have been developed exhibit poor therapeutic outcomes resulting from the inability of a therapeutic amount of the drug to reach the brain. These drugs do not exhibit targeted drug delivery mechanisms, resulting in a high concentration of the drugs in vital organs leading to drug toxicity. Chitosan (CS) is a natural-based polymer. It has unique properties such as good biodegradability, biocompatibility, mucoadhesive properties, and it has been approved for biomedical applications. It has been used to develop nanocarriers for brain targeting via intranasal administration. Nanocarriers such as nanoparticles, in situ gels, nanoemulsions, and liposomes have been developed. In vitro and in vivo studies revealed that these nanocarriers exhibited enhanced drug uptake to the brain with reduced side effects resulting from the prolonged contact time of the nanocarriers with the nasal mucosa, the surface charge of the nanocarriers, the nano size of the nanocarriers, and their capability to stretch the tight junctions within the nasal mucosa. The aforementioned unique properties make chitosan a potential material for the development of nanocarriers for targeted drug delivery to the brain. This review will focus on chitosan-based carriers for brain targeting.

show abstract

Brain targeting efficiency of antimigrain drug loaded mucoadhesive intranasal nanoemulsion

Cited by 98 publications

References 49 publications

Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders

Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders

Intranasal Nanoparticulate Systems as Alternative Route of Drug Delivery

Chitosan-Based Nanocarriers for Nose to Brain Delivery

Contact Info

Product

Resources

About